Merck & Co Inc [NYSE: MRK] stock went on a downward path that fall over -2.29% on Monday, amounting to a one-week price decrease of less than -3.72%. The company report on March 4, 2024 at 6:45 AM that Merck to Participate in the Leerink Partners Global Biopharma Conference 2024.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, is scheduled to participate in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024, at 12:40 p.m. ET.
Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink.
Over the last 12 months, MRK stock rose by 15.92%. The one-year Merck & Co Inc stock forecast points to a potential upside of 9.2. The average equity rating for MRK stock is currently 1.61, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $314.17 billion, with 2.53 billion shares outstanding and 2.53 billion shares in the current float. Compared to the average trading volume of 8.04M shares, MRK stock reached a trading volume of 12472111 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Merck & Co Inc [MRK]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRK shares is $136.62 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRK stock is a recommendation set at 1.61. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
TD Cowen have made an estimate for Merck & Co Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on January 04, 2024. While these analysts kept the previous recommendation, Deutsche Bank raised their target price to Buy. The new note on the price target was released on November 09, 2023, representing the official price target for Merck & Co Inc stock. Previously, the target price had yet another raise to $132, while BMO Capital Markets analysts kept a Outperform rating on MRK stock. On October 20, 2023, analysts increased their price target for MRK shares from 117 to 122.
The Average True Range (ATR) for Merck & Co Inc is set at 1.82, with the Price to Sales ratio for MRK stock in the period of the last 12 months amounting to 5.25. The Price to Book ratio for the last quarter was 8.36, with the Price to Cash per share for the same quarter was set at 2.83. Price to Free Cash Flow for MRK in the course of the last twelve months was 34.36 with Quick ratio for the last quarter at 1.00.
MRK Stock Performance Analysis:
Merck & Co Inc [MRK] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.72. With this latest performance, MRK shares dropped by -1.84% in over the last four-week period, additionally plugging by 13.83% over the last 6 months – not to mention a rise of 15.92% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRK stock in for the last two-week period is set at 45.36, with the RSI for the last a single of trading hit 32.66, and the three-weeks RSI is set at 53.21 for Merck & Co Inc [MRK]. The present Moving Average for the last 50 days of trading for this stock 120.77, while it was recorded at 127.08 for the last single week of trading, and 110.42 for the last 200 days.
Insight into Merck & Co Inc Fundamentals:
Merck & Co Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.25.
MRK Stock EPS
With the latest financial reports released by the company, Merck & Co Inc posted 1.4/share EPS, while the average EPS was predicted by analysts to be reported at 1.32/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 6.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Merck & Co Inc go to 67.41%.
Merck & Co Inc [MRK] Institutonal Ownership Details
The top three institutional holders of MRK stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in MRK stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in MRK stock with ownership which is approximately 5.8325%.
